Author + information
- Nan Jinglong,
- Xue LiYing,
- He WenShuai and
- Nan JingLong
Pulmonary arterial hypertension leads to increased pulmonary vascular resistance, vascular remodelling and plexiform lesions. Some recent studies have shown that inflammation has an important role in the pathophysiology of pulmonary arterial hypertension. The aim of this study is to evaluate Serum Pentraxin 3, NT-proBNPtandem and several other potential PAH biomarkers levels in pulmonary arterial hypertension (PAH)., and evaluate the role of inflammation in pulmonary hypertension.
After ethics committee approval and receiving consent from parents, a total of 31 patients, 5 with idiopathic PAH. (IPAH) and 26 with PAH associated with connective tissue disease (CTD), and 8 age-matched, non-relative controls were studied. After recording data about all the patients including age, gender, weight, haemodynamic studies and vasodilator testing, a physical examination was done for all subjects. Blood was taken from patients. Serum Pentraxin 3, N-terminal pro-Brain Natriuretic Peptide (NT-ProBNP) and hs-CRP levels were measured. Serum Pentraxin-3 levels were measured by enzyme linked immunosorbent assay (ELISA) and expressed as ng/mL. The serum concentration of NT-proBNP was determined by a chemiluminescent immunumetric assay and expressed as pg/mL.
Serum Pentraxin- 3 levels were determined to be 1.38±2.16 ng/mL in the PAH group and 0.42±0.65 ng/mL in control group. There was a statistically significant difference between the two groups (p<0.01). Serum NT-proBNP levels were measured as 2800.27±700.82 pg/mL in PAH group and 355.36±217.34 pg/mL control group.
Our study showed that Pentraxin 3 and NT-proBNP levels were increased significantly in the PAH group. We consider that inflammation plays an important role in severe pulmonary hypertension.